Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Get access
Powerful Medical
•
28. July 2025
•
3 min to read
  • Study

Failure of standard contemporary ST-elevation myocardial infarction electrocardiogram criteria to reliably identify acute occlusion of the left anterior descending coronary artery

Link to Publication

Overview

ST-elevation (STE) criteria on the electrocardiogram (ECG) are poorly sensitive for acute coronary occlusion myocardial infarction (ACOMI or OMI). This study evaluates the sensitivity of STE criteria on serial ECGs for total left anterior descending (LAD) coronary artery occlusion. We compared STE criteria with expert interpretation and a validated artificial intelligence (AI) ECG model for diagnosing LAD OMI.

Published in: European Heart Journal. Acute Cardiovascular Care
Published on: 28 July 2025

Background

The Queen of Hearts (QoH) ECG artificial intelligence (AI) model (PMcardio, Bratislava, Slovakia) has demonstrated improved sensitivity for detecting occlusion myocardial infarction (OMI) compared with STEMI criteria, but further validation in all-comer cohorts is needed. We aimed to evaluate QoH’s diagnostic performance for OMI detection in chest pain patients at Swedish emergency departments (EDs) and compare its accuracy to STEMI criteria.

Methods

This is a retrospective sub-study of the DOMI-ARIGATO case-control study of OMI (808 patients, 265 with OMI). All cases of total (TIMI-0 flow) LAD occlusion were assessed for STE criteria. An OMI ECG expert blindly interpreted all serial ECGs. An AI model (PMCardio Queen of Hearts) was applied to the first available 12-lead ECG.

Results

Among the 53 cases of acute LAD OMI with TIMI-0 flow, 20 (38%) did not meet STE myocardial infarction (STEMI) criteria on any pre-angiography ECG; 16/ 20 had at least two ECGs before angiography. Both the expert and AI model had 100% sensitivity for diagnosing LAD OMI on the first ECG in these 20 cases. Door-to-balloon time (DBT) was significantly shorter for those meeting STEMI criteria. Infarct size, measured by ejection fraction and peak troponin, did not differ between cases with and without STEMI criteria.

Conclusion

The STEMI criteria missed 38% of acute total LAD occlusions on all serial ECGs. Both expert interpretation and the AI model demonstrated 100% sensitivity on the first ECG for all cases. Despite the lack of STEMI criteria, these cases had similar infarct sizes but were associated with longer DBTs.

Failure of standard contemporary ST-elevation myocardial infarction electrocardiogram criteria to reliably identify acute occlusion of the left anterior descending coronary artery
Authors: Harvey Pendell Meyers, Scott W. Sharkey, Robert Herman, José Nunes de Alencar, Gautam R. Shroff, Willy H. Frick, and Stephen W. Smith

Link to Publication
Author-Logo_PM
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.

About PMcardio

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Relevant Publications

All Publications
  • Study
  • JACC Cardiovascular Interventions
  • October 28, 2025

AI-Enabled ECG Analysis Improves Diagnostic Accuracy and Reduces False STEMI Activations: A Multicenter U.S. Registry

In a large, multi-center evaluation presented as Late-Breaking Science at the TCT 2025 conference, investigators assessed the diagnostic accuracy of the Queen of Hearts™ AI algorithm for ST-segment elevation myocardial infarction (STEMI) detection in emergency care. The study compared AI-enhanced ECG interpretation against standard triage protocols across three U.S. PCI centers, encompassing more than 1,000 patients who activated emergent reperfusion pathways. Published in JACC: Cardiovascular Interventions, the results demonstrated significantly improved accuracy and reduced false activations when using AI-driven analysis.
  • Study
  • Journal of Electrocardiology
  • May 10, 2025

Electrocardiographic Diagnostic Possibilities for Atrial Fibrillation Using Artificial Intelligence: Differentiation from Sinus Rhythm and Other Arrhythmias with the Pmcardio App in Covid-19 Patients

This study evaluated how effectively artificial intelligence can detect atrial fibrillation (AF) in COVID-19 patients using ECG analysis. Researchers compared the PMcardio AI application’s performance with that of cardiologists and infectious disease specialists. Among 116 hospitalized COVID-19 patients, PMcardio achieved perfect diagnostic accuracy (sensitivity and specificity of 1.00) for AF detection, matching cardiologists and surpassing infectious disease specialists. The AI’s performance remained consistent across confidence levels, and its severity assessments correlated significantly with rhythm findings. These results highlight AI’s potential to improve arrhythmia detection, streamline care, and reduce unnecessary in-person evaluations during infectious disease outbreaks.
More articles

Join over 100,000 healthcare professionals who are already taking advantage of AI

Download PMcardio app on the Apple App Store
Get PMcardio app on Google Play Store

Ready to get started?

Get access

Powerful Medical is redefining the landscape of medical diagnostics with its AI-driven solutions. The company’s certified PMcardio platform revolutionizes the way cardiovascular diseases are detected, offering rapid and accurate diagnostics that pave the way for timely and effective treatment.

Logo of Next Gen EU
Logo of Next Gen EU

Products

Company

Resources

Legal

Envelope Linkedin-in Instagram Facebook-f

© Powerful Medical 2025

Privacy

&

Cookies

Legal

Powerful Medical, Inc. | PMcardio and the PMcardio logo are registered trademarks of Powerful Medical. Additionally, Queen of Hearts is claimed as a trademark of Powerful Medical.

 

PMcardio is CE-marked as class IIb medical device under EU MDR and only certified for marketing in the European Union and the United Kingdom. PMcardio technology has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA. Not all modules of the PMcardio platform may be available in your region.

Prior to use, reference the Instructions for Use, for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

PMcardio is CE-marked as class IIb medical device under EU MDR and only certified for marketing in the European Union and the United Kingdom. PMcardio technology has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA. Not all modules of the PMcardio platform may be available in your region. Prior to use, reference the Instructions for Use, for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Get access